BG106149A - Mutual prodrugs of amlodipine and atorvastatin - Google Patents

Mutual prodrugs of amlodipine and atorvastatin

Info

Publication number
BG106149A
BG106149A BG106149A BG10614901A BG106149A BG 106149 A BG106149 A BG 106149A BG 106149 A BG106149 A BG 106149A BG 10614901 A BG10614901 A BG 10614901A BG 106149 A BG106149 A BG 106149A
Authority
BG
Bulgaria
Prior art keywords
atorvastatin
amlodipine
relates
compositions
prodrugs
Prior art date
Application number
BG106149A
Other languages
Bulgarian (bg)
English (en)
Inventor
George Chang
Ernest Hamanaka
John LAMATTINA
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106149A publication Critical patent/BG106149A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BG106149A 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin BG106149A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (en) 1999-05-27 2000-03-20 Mutual prodrugs of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
BG106149A true BG106149A (en) 2002-05-31

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106149A BG106149A (en) 1999-05-27 2001-11-26 Mutual prodrugs of amlodipine and atorvastatin

Country Status (41)

Country Link
US (1) US6486182B1 (es)
EP (1) EP1180102B9 (es)
JP (1) JP2003500487A (es)
KR (1) KR20020012247A (es)
CN (1) CN1352640A (es)
AP (1) AP2001002345A0 (es)
AR (1) AR022344A1 (es)
AT (1) ATE268764T1 (es)
AU (1) AU3313900A (es)
BG (1) BG106149A (es)
BR (1) BR0011006A (es)
CA (1) CA2375372C (es)
CO (1) CO5170457A1 (es)
CZ (1) CZ20014229A3 (es)
DE (1) DE60011424T2 (es)
DK (1) DK1180102T3 (es)
DZ (1) DZ3048A1 (es)
EA (1) EA200101130A1 (es)
EE (1) EE200100631A (es)
ES (1) ES2220426T3 (es)
GT (1) GT200000078A (es)
HK (1) HK1046282A1 (es)
HN (1) HN2000000075A (es)
HR (1) HRP20010856A2 (es)
HU (1) HUP0201433A2 (es)
IL (1) IL145947A0 (es)
IS (1) IS6135A (es)
MA (1) MA26736A1 (es)
MX (1) MXPA01012125A (es)
NO (1) NO20015756L (es)
OA (1) OA11950A (es)
PA (1) PA8495701A1 (es)
PE (1) PE20010169A1 (es)
PL (1) PL353483A1 (es)
PT (1) PT1180102E (es)
SK (1) SK16792001A3 (es)
SV (1) SV2002000082A (es)
TN (1) TNSN00113A1 (es)
TR (1) TR200103391T2 (es)
WO (1) WO2000073298A1 (es)
ZA (1) ZA200109691B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
JP4905738B2 (ja) 2007-10-10 2012-03-28 Nok株式会社 アキュムレータ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
EE200100631A (et) 2003-02-17
EP1180102A1 (en) 2002-02-20
SK16792001A3 (sk) 2003-03-04
NO20015756D0 (no) 2001-11-26
HK1046282A1 (zh) 2003-01-03
DE60011424T2 (de) 2005-08-25
PL353483A1 (en) 2003-11-17
NO20015756L (no) 2002-01-24
CN1352640A (zh) 2002-06-05
MA26736A1 (fr) 2004-12-20
HRP20010856A2 (en) 2002-12-31
CA2375372C (en) 2007-01-09
CZ20014229A3 (cs) 2003-01-15
PT1180102E (pt) 2004-08-31
AP2001002345A0 (en) 2001-12-31
MXPA01012125A (es) 2002-06-04
ATE268764T1 (de) 2004-06-15
ES2220426T3 (es) 2004-12-16
DE60011424D1 (de) 2004-07-15
CO5170457A1 (es) 2002-06-27
DZ3048A1 (fr) 2004-03-27
EP1180102B9 (en) 2005-03-02
IL145947A0 (en) 2002-07-25
ZA200109691B (en) 2002-11-26
CA2375372A1 (en) 2000-12-07
SV2002000082A (es) 2002-02-05
HUP0201433A2 (en) 2002-08-28
WO2000073298A1 (en) 2000-12-07
EP1180102B1 (en) 2004-06-09
OA11950A (en) 2006-04-13
TR200103391T2 (tr) 2002-04-22
TNSN00113A1 (fr) 2005-11-10
HN2000000075A (es) 2001-02-02
US6486182B1 (en) 2002-11-26
PA8495701A1 (es) 2001-12-14
PE20010169A1 (es) 2001-02-10
EA200101130A1 (ru) 2002-04-25
KR20020012247A (ko) 2002-02-15
GT200000078A (es) 2001-11-16
JP2003500487A (ja) 2003-01-07
IS6135A (is) 2001-10-30
DK1180102T3 (da) 2004-09-06
AR022344A1 (es) 2002-09-04
AU3313900A (en) 2000-12-18
BR0011006A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
BG106128A (en) Mutual salt of amlodipine and atorvastatin
BG106149A (en) Mutual prodrugs of amlodipine and atorvastatin
FR2780730B1 (fr) Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
PL339092A1 (en) Therapeutic compositions containing amlodipin and atorvastatin
DE69728907T2 (de) Klebstoffzusammensetzungen beständig gegen hohe feuchtigkeit
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
CA2296726A1 (en) Combination therapy
MXPA01008371A (es) Metodo y equipo para reparar un componente de construccion.
DK1053240T3 (da) Glucocorticoid-selektiv antiinflammatoriske midler
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
GR1004124B (el) Ασπαρτικο παραγωγο της αμλοδιπινης.
LU90584B1 (de) Drahtfaser
DE69929024D1 (de) Immunschwächevirus Stamm FIV-141 der Katze und dessen Verwendungen
IS4783A (is) 1,4 -Díhýdrópýridín efnasambönd sem mótlyf gegn kínínseinkun
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
IL136119A0 (en) Flame resistant polyolefin compositions and methods for the preparation thereof
UY26164A1 (es) Profarmácos mutuos de amlodipino y atorvastatina
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina
TW413007U (en) Improved structure of stove for burning paper money for the dead
TW444833U (en) High tensile bolt set
IT1313237B1 (it) Componente strutturale multifunzionale per quadri elettrici,centralini e simili.
AUPQ065499A0 (en) Modified worker operationin textile carding
TW375144U (en) Improved structure of the pressing post for form work